Last reviewed · How we verify

Low-dose Clomiphene

Weill Medical College of Cornell University · FDA-approved active Small molecule ✓ Verified Jun 2026

Low-dose Clomiphene is a Selective estrogen receptor modulator (SERM) Small molecule drug developed by Weill Medical College of Cornell University. It is currently FDA-approved for Male hypogonadism / testosterone deficiency, Male infertility associated with low testosterone. Also known as: clomiphene citrate with low dose gonadotropins.

Low-dose clomiphene is a selective estrogen receptor modulator (SERM) that blocks negative feedback on the hypothalamic-pituitary-gonadal axis, stimulating endogenous testosterone production in men.

Low-dose Clomiphene is used to treat conditions such as Infertility, Secondary Hypogonadism, and Male Infertility, as indicated by ClinicalTrials.gov. It works as an estrogen receptor alpha modulator, a small molecule that interacts with the estrogen receptor, according to ChEMBL.

At a glance

Generic nameLow-dose Clomiphene
Also known asclomiphene citrate with low dose gonadotropins
SponsorWeill Medical College of Cornell University
Drug classSelective estrogen receptor modulator (SERM)
TargetEstrogen receptor (ER-α and ER-β)
ModalitySmall molecule
Therapeutic areaEndocrinology
PhaseFDA-approved

Mechanism of action

Clomiphene citrate acts as a partial antagonist at estrogen receptors in the hypothalamus and pituitary gland, preventing the normal inhibitory feedback of estrogen on gonadotropin-releasing hormone (GnRH) secretion. This leads to increased release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulate the testes to produce testosterone. At low doses, this effect is optimized to increase testosterone while minimizing suppression of spermatogenesis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Low-dose Clomiphene

What is Low-dose Clomiphene?

Low-dose Clomiphene is a Selective estrogen receptor modulator (SERM) drug developed by Weill Medical College of Cornell University, indicated for Male hypogonadism / testosterone deficiency, Male infertility associated with low testosterone.

How does Low-dose Clomiphene work?

Low-dose clomiphene is a selective estrogen receptor modulator (SERM) that blocks negative feedback on the hypothalamic-pituitary-gonadal axis, stimulating endogenous testosterone production in men.

What is Low-dose Clomiphene used for?

Low-dose Clomiphene is indicated for Male hypogonadism / testosterone deficiency, Male infertility associated with low testosterone.

Who makes Low-dose Clomiphene?

Low-dose Clomiphene is developed and marketed by Weill Medical College of Cornell University (see full Weill Medical College of Cornell University pipeline at /company/weill-medical-college-of-cornell-university).

Is Low-dose Clomiphene also known as anything else?

Low-dose Clomiphene is also known as clomiphene citrate with low dose gonadotropins.

What drug class is Low-dose Clomiphene in?

Low-dose Clomiphene belongs to the Selective estrogen receptor modulator (SERM) class. See all Selective estrogen receptor modulator (SERM) drugs at /class/selective-estrogen-receptor-modulator-serm.

What development phase is Low-dose Clomiphene in?

Low-dose Clomiphene is FDA-approved (marketed).

What are the side effects of Low-dose Clomiphene?

Common side effects of Low-dose Clomiphene include Visual disturbances (blurred vision, scotomata), Hot flashes, Mood changes / irritability, Headache, Nausea.

What does Low-dose Clomiphene target?

Low-dose Clomiphene targets Estrogen receptor (ER-α and ER-β) and is a Selective estrogen receptor modulator (SERM).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing